Published in PLoS One on April 27, 2012
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest (2013) 1.44
Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther (2013) 0.97
Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther (2013) 0.95
Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. Brain (2015) 0.93
Long-term nonsense suppression therapy moderates MPS I-H disease progression. Mol Genet Metab (2013) 0.91
Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis (2013) 0.89
Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV. Acta Neuropathol Commun (2014) 0.82
Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy. Mol Ther (2015) 0.82
Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I. J Biol Chem (2014) 0.82
Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. Mol Ther (2015) 0.81
Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood. PLoS One (2013) 0.81
Sanfilippo syndrome: causes, consequences, and treatments. Appl Clin Genet (2015) 0.79
Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease. Behav Brain Res (2015) 0.78
Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H. Sci Rep (2016) 0.77
Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab (2014) 0.76
Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Curr Opin Pediatr (2015) 0.76
Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci (2015) 0.76
Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III). Hum Mol Genet (2014) 0.76
Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery. Mol Ther (2017) 0.76
Ganglioside accumulation in activated glia in the developing brain: comparison between WT and GalNAcT KO mice. J Lipid Res (2015) 0.75
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC. Dis Model Mech (2016) 0.75
A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease. Dis Model Mech (2016) 0.75
Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice. Sci Rep (2017) 0.75
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice. Mol Ther Methods Clin Dev (2017) 0.75
Assessment of dysmyelination with RAFFn MRI: application to murine MPS I. PLoS One (2015) 0.75
Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Mol Genet Metab (2016) 0.75
Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I. PLoS One (2015) 0.75
Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB. Metab Brain Dis (2017) 0.75
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol (2005) 6.16
Molecular diversity of heparan sulfate. J Clin Invest (2001) 5.40
SNARE function analyzed in synaptobrevin/VAMP knockout mice. Science (2001) 4.09
Signal-processing machines at the postsynaptic density. Science (2000) 3.47
A block of autophagy in lysosomal storage disorders. Hum Mol Genet (2007) 3.28
Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science (2001) 3.22
Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A (2003) 2.96
Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab (2004) 2.46
Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J (2006) 2.41
Sanfilippo syndrome: a mini-review. J Inherit Metab Dis (2008) 2.35
Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A (2000) 2.11
Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem (1998) 1.97
Autophagy in neurons: a review. Histol Histopathol (2002) 1.96
Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet (2002) 1.95
Innate and adaptive immune activation in the brain of MPS IIIB mouse model. J Neurosci Res (2009) 1.90
Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet (1997) 1.81
Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc Natl Acad Sci U S A (1999) 1.79
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol (2004) 1.74
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology (1999) 1.67
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem (2000) 1.46
Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav (2005) 1.43
Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One (2010) 1.42
Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol (2004) 1.34
Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta (2008) 1.30
Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One (2008) 1.30
Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab (2009) 1.26
Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One (2007) 1.23
A simplified and sensitive fluorescent method for disaccharide analysis of both heparan sulfate and chondroitin/dermatan sulfates from biological samples. Glycobiology (2008) 1.23
Lysosomal disorders. Semin Neonatol (2002) 1.21
Cellular functions of proteoglycans--an overview. Semin Cell Dev Biol (2001) 1.21
The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med (2008) 1.18
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res (2006) 1.14
Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab (2004) 1.04
Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes Brain Behav (2008) 1.04
Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem Soc Trans (2006) 1.03
Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol (2004) 1.03
Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci (2009) 1.02
Complex, multimodal behavioral profile of the Homer1 knockout mouse. Genes Brain Behav (2007) 1.02
Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav Brain Res (2010) 0.99
Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J Neurochem (1978) 0.98
Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol Genet Metab (2009) 0.95
Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test. PLoS One (2011) 0.93
Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments. Genes Brain Behav (2011) 0.93
Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase. J Biol Chem (2011) 0.93
Developmental roles for Homer: more than just a pretty scaffold. J Neurochem (2008) 0.89
Roles of heparan sulfate in mammalian brain development current views based on the findings from Ext1 conditional knockout studies. Prog Mol Biol Transl Sci (2010) 0.87
Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. Mol Genet Metab (2005) 0.86
Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol Cell Neurosci (2009) 0.82
Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses. NMR Biomed (2003) 0.77
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol (2006) 3.45
Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells (2004) 3.15
A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 2.90
The bone marrow functionally contributes to liver fibrosis. Gastroenterology (2006) 2.52
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res (2007) 2.10
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med (2005) 2.06
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
The role of human HtrA1 in arthritic disease. J Biol Chem (2005) 1.91
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol (2009) 1.84
Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther (2008) 1.82
Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2004) 1.75
A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur J Immunol (2011) 1.70
Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis (2006) 1.69
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol (2008) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther (2005) 1.66
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A (2005) 1.66
Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal. Stem Cells (2009) 1.63
Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr (2005) 1.63
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nat Commun (2013) 1.58
The heparanome--the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol (2007) 1.57
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry (2012) 1.56
Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis (2011) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr (2009) 1.52
Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. Biochem J (2006) 1.48
Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A (2005) 1.47
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. J Biol Chem (2004) 1.42
Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One (2010) 1.42
12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J Immunol (2008) 1.38
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol (2012) 1.36
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum (2006) 1.36
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res (2004) 1.32
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood (2004) 1.30
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Effects of cis-regulatory variation differ across regions of the adult human brain. Hum Mol Genet (2010) 1.27
High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem (2005) 1.27
The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem (2003) 1.27
Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab (2009) 1.26
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26
Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Hum Mol Genet (2009) 1.26
Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell (2009) 1.25
The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 1.24
An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet (2002) 1.24
Analytical strategies for characterization of oxysterol lipidomes: liver X receptor ligands in plasma. Free Radic Biol Med (2012) 1.23
Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet (2013) 1.23
Essential alterations of heparan sulfate during the differentiation of embryonic stem cells to Sox1-enhanced green fluorescent protein-expressing neural progenitor cells. Stem Cells (2007) 1.23
Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol (2009) 1.22
Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J (2011) 1.22
Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog (2008) 1.21
Abnormal telomere shortening in leucocytes of children with Shwachman-Diamond syndrome. Br J Haematol (2002) 1.19
Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem (2009) 1.18
Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol (2004) 1.14
Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol Dis (2005) 1.14
Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp Neurol (2009) 1.13
Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol Dis (2005) 1.11
Immunosuppression alters disease severity in juvenile Batten disease mice. J Neuroimmunol (2011) 1.10
Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis (2012) 1.09
Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis (2006) 1.08
Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res (2009) 1.08
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum (2006) 1.07
Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J Neuropathol Exp Neurol (2008) 1.07
DHHC5 interacts with PDZ domain 3 of post-synaptic density-95 (PSD-95) protein and plays a role in learning and memory. J Biol Chem (2010) 1.07
Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 1.06
Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol (2012) 1.05
Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol (2004) 1.04
p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol Cell Neurosci (2004) 1.04
Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol (2004) 1.03
Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet (2011) 1.03
Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 1.03
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Specific glycosaminoglycans modulate neural specification of mouse embryonic stem cells. Stem Cells (2011) 1.03
IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol Dis (2006) 1.03
Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis (2010) 1.02
Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood (2010) 1.02
Immune system irregularities in lysosomal storage disorders. Acta Neuropathol (2007) 1.02
Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis (2010) 1.01
Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS One (2012) 1.01
Macrophage heterogeneity and acute inflammation. Eur J Immunol (2011) 1.01
Enhanced neutrophil migratory activity following major blunt trauma. Injury (2005) 1.01
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J (2010) 1.01
Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther (2012) 1.00